Content area
Full text
Received May 16, 2017; Accepted Oct 8, 2017
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. Introduction
Metabolic syndrome (MetS) is a cluster of metabolic symptoms including abdominal obesity, hypertension, dyslipidaemia, and insulin resistance (IR) [1]. Several frequently used definitions of MetS currently exist, including definitions proposed by the World Health Organization (WHO) [2], the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) [3], the International Diabetes Federation (IDF) [4], the International Diabetes Federation (IDF), and the American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) [5]. They show different reference values and variations concerning the metabolic parameters associated with the syndrome.
MetS has become an increasing problem in our society. The prevalence of MetS has increased as a result of the increasing prevalence of obesity and sedentary lifestyles [6]. In the United States, approximately 25% of adults have been diagnosed with metabolic syndrome [7]. According to the results of epidemiological studies, the prevalence of MetS in China is 13.3% [8].
A systematic review showed that MetS was associated with a high risk for diabetes, cardiovascular disease (CVD), CVD mortality, and stroke [9]. Therefore, it is very important to prevent, treat, and control MetS. Lifestyle modification is the essential strategy for MetS prevention and treatment and includes weight control, diet management, exercise, and smoking cessation [10, 11]. Drug therapy includes statins, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II...